Central blood pressure lowering effect of telmisartan-rosuvastatin single-pill combination in hypertensive patients combined with dyslipidemia: A pilot study

This multicenter, phase 4, Prospective Randomized Open, Blinded End-point (PROBE) study aimed to evaluate safety and efficacy of telmisartan/rosuvastatin single-pill combination (SPC) therapy on lowering central blood pressure (BP) compared with telmisartan monotherapy in hypertensive patients with dyslipidemia in Korea. Study was terminated earlier than planned due to COVID-19 pandemic, thus should be considered as a pilot study. Among 125 patients who met the inclusion criteria of hypertension and dyslipidemia (defined as 10-year Atherosclerotic Cardiovascular Disease risk score over 5%), 80 patients went through 4-week single-group run-in period with telmisartan 40-80 mg, then randomized to telmisartan 80 mg + rosuvastatin (10 or 20 mg) SPC group or telmisartan 80 mg monotherapy group. The central/brachial BP, brachial-ankle pulse wave velocity (baPWV), and augmentation index (AIx) were assessed at baseline and 16 weeks later. Mean brachial SBP changed from 135.80 +/- 14.22 mmHg to 130.69 +/- 13.23 mmHg in telmisartan/rosuvastatin group and from 134.37 +/- 12.50 mmHg to 133.75 +/- 12.30 mmHg in telmisartan monotherapy group without significant difference (between-group difference p = .149). Mean central SBP were reduced significantly in the telmisartan/rosuvastatin group with change from 126.72 +/- 14.44 mmHg to 121.56 +/- 14.56 mmHg while telmisartan monotherapy group showed no significant change (between-group difference p = .028). BaPWV changed from 1672.57 +/- 371.72 m/s to 1591.75 +/- 272.16 m/s in telmisartan/rosuvastatin group and from 1542.85 +/- 263.70 m/s to 1586.12 +/- 297.45 m/s in telmisartan group with no significance (between-group difference p = .078). Change of AIx had no significant difference (between-group difference p = .314). Both groups showed excellent compliance rate of 96.9 +/- 4.5% with no significant difference in adverse rate. Telmisartan/rosuvastatin SPC therapy was more effective in lowering central BP compared with the telmisartan monotherapy. The results of this study showed benefit of additive statin therapy in hypertensive patients combined with dyslipidemia.

Automated summary

This study aimed to evaluate the safety and efficacy of telmisartan/rosuvastatin single-pill combination therapy in reducing central blood pressure compared to telmisartan monotherapy. The results showed that the combination therapy was more effective in lowering central blood pressure, indicating the potential benefit of adding statin therapy for hypertensive patients with dyslipidemia. Both groups showed high compliance and no significant difference in adverse events.